020 Evidence for altered peroxisome proliferator activated receptor (PPAR) pathway activity in a transgenic mouse model of scleroderma (TbRIIDk-fib): analysis of mouse skin, lung and explanted cells

Emma C. Derrett‐Smith, Rachel K. Hoyles, X. Shiwen et al. · Lara D. Veeken · 2019

Background: The TβRIIΔk-fib transgenic (TG) mouse model of scleroderma replicates key features of scleroderma, including susceptibility to lung fibrosis and pulmonary hypertension. This study examines evidence of peroxisome proliferator-activated receptor (PPAR) pathway perturbation in tissue or explanted cells from TG mice compared with wildtype (WT) littermates. Lanifibranor is a new chemical entity that activates all PPAR isoforms and is undergoing clinical trials in scleroderma at present. Methods: Gene expression differences between whole skin biopsies, fibroblasts or aortic smooth muscle cells (aSMCs) from TβRIIΔk-fib and WT sex-matched littermate mice (n = 3 each group; 42 profiles) were quantified using MouseRef-8v1.1 expression BeadChips. After normalisation, genes were ranked according to differential expression, expressed as pairwise analysis comparing mean expression of two groups (T test), with FDR correction for multiple testing (number of tests/rank of p value). The PPAR pathway gene list from http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_PPAR_SIGNALING_PATHWAY was cross-referenced with each microarray. Within the GSEA cohort the number with significant differential expression or trend to difference (P < 0.10) was determined. 12,800 genes were tested. Results: The genes within the PPAR pathway showing either significant difference (p < 0.05) or trend of difference are summarised in Table 1. 11 genes showed significant difference between WT and TG explant cells and 82% (n = 9) were reduced in the TG cells. 25 genes showed a trend of difference in ⩾ 1 of the test substrates and the majority, 18 (72%), were down-regulated in TG, suggesting down-regulation of the PPAR pathway in the TβRIIΔk-fib mouse model. There were most differences in aSMCs: the altered phenotype of these in culture is likely to reflect an altered in vivo environment, with elevated TGFβ activity in the vessel wall rather than intrinsic SMC abnormalities since the SMC do not express the transgene. Conclusion: These results are not indicative of highly dysregulated PPAR pathway expression, although overall there is a signal that the PPAR pathway, assessed by GSEA, may be reduced in TG mice. This trend is seen most often in aSMC explant culture. This mouse model provides a potential platform for in vivo experiments to provide mechanistic support for trials of lanifibranor in scleroderma. Dysregulated PPAR pathway gene expression in TG mice italics p < 0.1; caps p < 0.05. Disclosures: E. Derrett-Smith: None. R. Hoyles: None. X. Shi-Wen: None. O. Lacombe: None. P. Broqua: None. J. Junien: None. I. Konstantinova: None. C.P. Denton: None.

Cited by 0 works. doi:10.1093/rheumatology/kez106.019

Authors